8-K Announcements
6Material company update
Jun 2, 2026·SEC
Material company update
May 21, 2026·SEC
Material company update
May 14, 2026·SEC
Fulgent Genetics, Inc.(FLGT)Earnings, Financials & Key Ratios
FLGT•NASDAQ
$21.02
Price updated Jul 7, 2026
AboutFulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.Show more
- Revenue$323M+13.8%
- EBITDA-$67M-36.7%
- Net Income-$61M-41.7%
- EPS (Diluted)-1.97-39.7%
- Gross Margin40.56%+7.2%
- EBITDA Margin-20.76%-20.1%
- Operating Margin-28.23%-8.3%
- Net Margin-18.75%-24.5%
- ROE-5.41%-43.4%
FLGT Price & Volume
Fulgent Genetics, Inc. (FLGT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Margin Compression Challenges Fulgent's Strategic Pivot
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Operating margin contraction risk
Key Thesis Takeaways
- Fulgent Genetics faces a difficult transition as it attempts to pivot from pandemic-era testing to core NGS services, evidenced by a 3.2% year-over-year revenue decline in 2026Q1.
- The company's aggressive capital allocation, including a $40.1M share buyback in 2026Q1, appears disconnected from its underlying operational performance, which saw operating margins plummet to -48.7%.
- Investors should monitor the rapid depletion of cash reserves, which fell from $117.6 million in 2025Q3 to $23.4 million in 2026Q1, as the firm struggles to achieve a sustainable path to profitability.
Verdict Logic
the company's decision to execute a $40.1M share buyback in 2026Q1 while reporting a net loss of $24.8M and a -48.7% operating margin suggests a concerning misalignment between capital deployment and operational sustainability.
FLGT Growth Metrics
Fulgent Genetics, Inc. (FLGT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years42.15%
5 Years-5.21%
3 Years-19.52%
TTM9.54%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-81.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-78.95%
Return on Capital
10 Years13.67%
5 Years12.33%
3 Years-10.1%
Last Year-8.01%
FLGT Recent Earnings
Fulgent Genetics, Inc. (FLGT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$0.36-3.4%
$0.35
Rev
$71M+4.5%
$68M
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.16+433.3%
$0.03
Rev
$83M-2.4%
$85M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.14+158.3%
$0.24
Rev
$84M-1.5%
$85M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.07+130.4%
$0.23
Rev
$82M+0.5%
$81M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.36vs $0.35-3.4% | $71Mvs $68M+4.5% |
| Q1 2026 | Feb 27, 2026 | $0.16vs $0.03+433.3% | $83Mvs $85M-2.4% |
| Q4 2025 | Nov 7, 2025 | $0.14vs $0.24+158.3% | $84Mvs $85M-1.5% |
| Q3 2025 | Aug 1, 2025 | $0.07vs $0.23+130.4% | $82Mvs $81M+0.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Fulgent Genetics, Inc. (FLGT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.02 | $596.98M | -10.67 | 13.83% | -18.75% | -5.41% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — | |
| $283.86 | $23.36B | 27.14 | 7.25% | 6.66% | 10.89% | — | |
| $212.38 | $23.51B | 24.27 | 11.78% | 9.08% | 13.8% | — |
Compare FLGT vs Peers
Fulgent Genetics, Inc. (FLGT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FLGT SEC Filings & Documents
Fulgent Genetics, Inc. (FLGT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when FLGT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FLGT Frequently Asked Questions
Fulgent Genetics, Inc. (FLGT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Fulgent Genetics, Inc.'s revenue?
Fulgent Genetics, Inc. (FLGT) reported $320.3M in revenue for fiscal year 2025. This represents a 24966% increase from $1.3M in 2014.
How fast is Fulgent Genetics, Inc. growing?
Fulgent Genetics, Inc. (FLGT) grew revenue by 13.8% over the past year. This is steady growth.
Is FLGT profitable?
Fulgent Genetics, Inc. (FLGT) reported a net loss of $73.8M for fiscal year 2025.
Dividend & Returns
What is FLGT's return on equity?
Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.
What is Fulgent Genetics, Inc.'s free cash flow?
Fulgent Genetics, Inc. (FLGT) had negative free cash flow of $113.2M in fiscal year 2025, likely due to heavy capital investments.